Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Clinical trial NCT01959698 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT01959698
Sponsor: Roswell Park Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

CD20 Positive Recurrent Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Stage I Diffuse Large B-Cell Lymphoma Stage II Diffuse Large B-Cell Lymphoma Stage III Diffuse Large B-Cell Lymphoma Stage IV Diffuse Large B-Cell Lymphoma

Start date: 2014-04-17
Primary completion: 2020-06-01
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.